Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Takeda Pharmaceutical Company Limited    4502   JP3463000004

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report  
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Takeda Pharmaceutical : Shire and SAIIDAC announce planned delisting of notes from the New York Stock Exchange

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/14/2019 | 09:53am EDT

Dublin - Shire plc ('Shire') and Shire Acquisitions Investments Ireland DAC, an Irish designated activity company and wholly-owned subsidiary of Shire ('SAIIDAC'), announced today that they have notified the New York Stock Exchange (the 'NYSE') of their intention to apply for the voluntary delisting of SAIIDAC's outstanding 1.900% Senior Notes due 2019, 2.400% Senior Notes due 2021, 2.875% Senior Notes due 2023 and 3.200% Senior Notes due 2026 (collectively, the 'Notes'), which are guaranteed by Shire.

Background and reasons for the delisting

The Notes were originally issued on September 23, 2016. Pursuant to Rule 12h-5 under the United States Securities Exchange Act of 1934, as amended (the 'Exchange Act'). However, SAIIDAC has been exempt from the periodic reporting requirements under the Exchange Act in connection with the Notes since Shire has been including in its financial statements a footnote providing the condensed consolidating financial information of SAIIDAC required to be included therein by Rule 3-10 of Regulation S-X.

On January 8, 2019, Takeda Pharmaceutical Company Limited (TSE: 4502, NYSE: TAK), a Japanese joint-stock corporation ('Takeda'), acquired all of the issued and to-be-issued share capital of Shire pursuant to a Scheme of Arrangement under Article 125 of the Companies (Jersey) Law 1991, as amended. As a result, Shire and SAIIDAC became wholly-owned subsidiaries of Takeda, and the listings of Shire's common shares on the London Stock Exchange and of American Depositary Shares ('ADSs') representing Shire's common shares on the NASDAQ Global Market were terminated.

Shire intends to file with the United States Securities and Exchange Commission (the 'Commission'), among other things, a notice on Form 15 to suspend the periodic reporting requirements under the Exchange Act applicable to it in connection with the terminated listing of its ADSs. Shire also intends to take the necessary steps to suspend the periodic reporting requirements under the Exchange Act applicable to it or its other subsidiaries in connection with any other class of securities, including the outstanding 1.875% Senior Notes due 2020, 3.600% Senior Notes due 2022, 4.000% Senior Notes due 2025 and 5.250% Senior Notes due 2045 issued by Baxalta and subsequently guaranteed by Shire (collectively, the 'Baxalta Notes').

Given these circumstances, Shire, SAIIDAC and Takeda have concluded that the costs of compliance, the demands on management's time and the resources required to maintain the listing of the Notes on the NYSE and to satisfy the periodic reporting obligations applicable to the Notes under the Exchange Act are greater than the benefits received by the Shire, SAIIDAC and Takeda and the holders of the Notes, and have decided to terminate the listing of the Notes on the NYSE.

Delisting Schedule

Shire and SAIIDAC intend to file an application on Form 25 for the voluntary delisting of the Notes no fewer than 10 days following the publication of this notice and the delivery of the related notice to the NYSE of their intention to apply for delisting. It is currently expected that such filing will occur on or around January 21, 2019. Under the rules of the Commission, the delisting will become effective 10 days following the filing of the Form 25, or on or around January 31, 2019. On the date such delisting becomes effective, Shire and SAIIDAC also intend to file with the Commission a notice of suspension of periodic reporting obligations under the Exchange Act on Form 15, at which time the periodic reporting obligations in connection with the Notes will be suspended.

Future Plans and Proposed Alternative Listing

Following the completion of the delisting and deregistration/suspension process described above, neither of Shire nor SAIIDAC will file periodic reports with the Commission in connection with the Notes. As noted above, Shire also intends to take the necessary steps to suspend the periodic reporting requirements under the Exchange Act applicable to it or its other subsidiaries in connection with any other class of securities, and it is expected that such requirements will be suspended substantially simultaneously with those relating to the Notes.

Takeda will continue to file periodic reports with the Commission in connection with the listing of its ADSs on the NYSE.

SAIIDAC has not, and does not intend to, arrange for the listing and/or registration on another national securities exchange, as defined under the Exchange Act, or for quotation of its security in a quotation medium, as defined in Rule 15d2-11 under the Exchange Act. SAIIDAC intends to apply for the listing of the Notes on the Singapore Exchange Securities Trading Limited, with the listing expected to occur following the completion of the delisting and deregistration/suspension process described above.

Following the completion of the delisting and deregistration/suspension process described above, Takeda also intends to guarantee the respective obligations of SAIIDAC under the Notes and of Baxalta under the Baxalta Notes. However, as neither of the Notes nor the Baxalta Notes will be subject to periodic reporting obligations under the Exchange Act, Takeda does not plan to include in its financial statements a footnote containing the condensed consolidating financial information of SAIIDAC or Shire contemplated by Rule 3-10 of Regulation S-X.

Contact:

Tel: +41 41 288 4195

Forward-Looking Statements

This release contains statements about Shire, SAIIDAC and Takeda that are or may be forward looking statements, including all statements other than statements of historical facts. Such forward looking statements often, but not always, include words such as 'targets', 'plans', 'believes', 'hopes', 'continues', 'expects', 'aims', 'intends', 'will', 'may', 'should', 'would', 'could', 'anticipates', 'estimates', 'projects' or words or terms of similar substance or the negative thereof. By their nature, forward-looking statements involve risk and uncertainty, because they relate to events and depend on circumstances that will occur in the future. The factors described in the context of such forward-looking statements herein could cause actual results and developments to differ materially from those expressed in or implied by such forward-looking statements. Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct and you are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as at the date of this release.

Risk factors that may affect the future results of Takeda, Shire and their subsidiaries are contained in Takeda's Registration Statement on Form 20-F, including the risks outlined under 'Item 3. Key Information-D. Risk Factors', and in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in 'ITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.takeda.com, www.shire.com and www.sec.gov). The contents of such reports are not incorporated by reference into, nor do they form part of, this release. These risk factors expressly qualify all forward-looking statements contained in this release and should also be considered by the reader.

All forward-looking statements attributable to Takeda, Shire or SAIIDAC or any person acting on their behalf are expressly qualified in their entirety by this cautionary statement. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Except to the extent otherwise required by applicable law, neither Takeda nor Shire nor SAIIDAC undertake any obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise.

(C) 2019 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
SHIRE 2.42% 4690 End-of-day quote.0.00%
TAKEDA PHARMACEUTICAL COMPANY LIMITED -1.28% 3780 End-of-day quote.4.42%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TAKEDA PHARMACEUTICAL COMP
06:38aTAKEDA PHARMACEUTICAL : Retrospective Real-World Comparative Analysis Highlights..
AQ
02:01aTAKEDA PHARMACEUTICAL : Retrospective Real-World Comparative Analysis Highlights..
PU
01:02aTAKEDA PHARMACEUTICAL : Retrospective Real-World Comparative Analysis Highlights..
BU
10/15Takeda sells Mideast, Africa drug portfolio to Switzerland's Acino
RE
10/15TAKEDA PHARMACEUTICAL : Agrees to divest select otc and non-core assets to acino..
PU
10/01TAKEDA PHARMACEUTICAL : Working Mother Names Takeda as One of the 2019 100 Best ..
AQ
09/27TAKEDA PHARMACEUTICAL : New Data Presented at World Sleep Congress Demonstrate E..
AQ
09/27TAKEDA PHARMACEUTICAL : New Data Presented at World Sleep Congress Demonstrate E..
AQ
09/27TAKEDA PHARMACEUTICAL CO LTD : Ex-dividend day for interim dividend
FA
09/25TAKEDA PHARMACEUTICAL : New Data Presented at World Sleep Congress Demonstrate E..
BU
More news
Financials (JPY)
Sales 2020 3 327 B
EBIT 2020 -47 541 M
Net income 2020 -292 922 M
Debt 2020 4 304 B
Yield 2020 4,76%
P/E ratio 2020 -20,1x
P/E ratio 2021 38,2x
EV / Sales2020 3,07x
EV / Sales2021 2,93x
Capitalization 5 918 B
Technical analysis trends TAKEDA PHARMACEUTICAL COMP
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Average target price 5 305,38  JPY
Last Close Price 3 780,00  JPY
Spread / Highest target 66,7%
Spread / Average Target 40,4%
Spread / Lowest Target -2,12%
EPS Revisions
Managers
NameTitle
Christophe Weber President, CEO & Representative Director
Costa Saroukos Chief Financial Officer
Andrew S. Plump Director, Chief Medical & Scientific Officer
Yasuhiko Yamanaka Director
Masato Iwasaki Director & President-Japan Pharma Business Unit
Sector and Competitors
1st jan.Capitalization (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED4.42%54 291
JOHNSON & JOHNSON-1.05%337 021
ROCHE HOLDING AG18.88%250 869
MERCK AND COMPANY10.82%216 813
PFIZER-16.47%201 662
NOVARTIS15.10%198 751